Jack Henry (JKHY) Q3 2026 earnings review
Strong Q3 Revisions Obscure Approaching Q4 Margin Pressures
Jack Henry delivered a robust Q3 with GAAP revenue up 8.7% and EPS jumping 12.2%, beating its own growth trajectory and prompting management to raise full-year FY26 guidance across the board. The topline was driven by record competitive core wins and sustained cloud migrations. However, the optics are slightly flattering: management explicitly warned of impending 'relative weakness' in Q4 as the temporary benefit of unusually low medical claims in the first half normalizes. Furthermore, the Payments segment—historically a steady engine—is decelerating noticeably. Despite these second-half headwinds, exceptional operating cash flow (+46% YTD) has fueled an aggressive $159M buyback in Q3 alone.
🐂 Bull Case
The company secured 17 competitive core wins in Q3, marking the best third-quarter performance in seven years. This locks in high-visibility, long-term recurring revenue.
With Year-to-Date Operating Cash Flow surging 46% to $459M, management leaned heavily into share repurchases, executing $159M in Q3 (vs $125M in Q2 and $100M through October).
🐻 Bear Case
The impressive 20.6% YTD GAAP operating income growth was artificially inflated by lower-than-normal medical claims. Management expects Q4 margins to contract as these costs normalize.
The Payments segment, traditionally a robust growth pillar, saw Non-GAAP Adjusted Revenue growth decelerate to just 4.7% in Q3, lagging significantly behind Core (+8.6%) and Complementary (+7.2%).
⚖️ Verdict: 🟢
Bullish. The core business is executing flawlessly, evidenced by the 17 new core wins and raised full-year guidance. While Q4 margin normalization and Payments softness warrant monitoring, the massive cash generation and resulting buybacks provide a high floor for the stock.
Key Themes
Core Sales and Cloud Migrations Accelerating
Core segment non-GAAP adjusted revenue grew 8.6% in Q3, outperforming total company averages. Management highlighted 17 competitive core wins—the strongest Q3 in seven years. Furthermore, data processing and hosting revenue within private/public cloud grew 9.4%. This shift to cloud-hosted environments structurally improves margin and locks in highly predictable recurring revenue streams.
Payments Segment Lags the Broader Portfolio
Decelerating. Payments segment non-GAAP adjusted revenue grew a meager 4.7% in Q3, down from 6.4% in Q2. While Faster Payments modules surged 46.4%, the much larger legacy card and processing volumes are likely facing tougher macroeconomic comparables and normalization of consumer spend. If this weakness persists, it could drag down Jack Henry's broader growth algorithm next year.
Medical Costs Mask True Run-Rate Margins
A key contradiction to the headline margin expansion is management's explicit warning regarding Q4. Jack Henry's self-insured medical plan experienced exceptionally low claims in the first half of FY26. As those costs normalize in Q4, margins are expected to contract sequentially. Investors should not extrapolate YTD operating margins (26.2% GAAP) as the new baseline going into FY27.
Macro Backdrop & Competitive Uncertainty Fueling Demand
CEO Greg Adelson explicitly cited 'increased technology spending and competitive uncertainty' as primary catalysts expanding the sales pipeline. Jack Henry is successfully capitalizing on the disruption caused by competitor core consolidations, positioning its modern, API-first platform as a stable, innovative alternative for regional banks and credit unions.
Faster Payments and Digital Product Adoption
Innovation continues to translate into immediate top-line growth. 'Faster payments' processing revenue skyrocketed 46.4% in Q3, building on the 55% volume growth reported earlier in the fiscal year. Digital and transaction revenues also posted a robust 9.9% growth rate, reflecting strong end-user adoption of Banno and real-time payment networks (Zelle, RTP, FedNow).
Deconversions Inflate GAAP, Muddying the Core Narrative
Elevated M&A activity across the financial institution landscape continues to generate one-time deconversion revenue. Q3 saw $18.6M in deconversion revenue, up significantly from $9.6M a year ago. While this provides a short-term cash windfall, it represents the loss of future recurring revenue. Jack Henry must adjust non-GAAP figures downwards by over $33M YTD just to show underlying operational health.
Other KPIs
Accelerating dramatically. Up 46% from $314.4M in the prior year period. This massive influx is primarily driven by higher net income and significant positive swings in deferred revenue and deferred income taxes. This cash generation enabled Jack Henry to pay down debt from $170M a year ago to $90M, while simultaneously accelerating stock buybacks.
Accelerating. R&D grew 14.5% YoY, outpacing revenue growth and increasing its margin footprint from 6.7% to 7.1%. Management is heavily investing in personnel to support the continued modernization of the Jack Henry Platform and the rollout of new SMB and embedded finance solutions.
Guidance
Stable. The midpoint of $2.485B was raised from previous expectations and implies an approximate 6.8% YoY growth rate over FY25's adjusted revenue. However, achieving this requires navigating the guided Q4 deceleration.
Accelerating. Raised from the prior $6.61 - $6.72 range. This represents roughly 9-10% YoY growth compared to FY25 ($6.24), fueled by higher operating income and a lower outstanding share count resulting from the $284M YTD buybacks.
Stable. Up from 23.1% in FY25. Despite the warning of Q4 contraction due to medical claims normalizing, the full-year margin profile still structurally expands by ~80-100 basis points year-over-year, showcasing excellent operating leverage.
Key Questions
Payments Segment Softness
Non-GAAP adjusted revenue in the Payments segment decelerated to 4.7% growth. How much of this is driven by macro-level consumer debit/credit spend normalization versus competitive losses or pricing compression?
Q4 Margin Contraction Quantification
You've warned about relative weakness in Q4 margins due to normalizing medical claims. Can you quantify the specific basis point benefit medical claims provided in H1 so we can accurately build the run-rate model for FY27?
Core Win Implementation Timeline
With a record 17 competitive core wins this quarter, what is the expected average lag time between signing these deals and the commencement of meaningful recurring revenue recognition?
M&A Deconversion Outlook
Deconversion revenue nearly doubled YoY in Q3 to $18.6M. Are you seeing an acceleration in the consolidation of your specific client base, and how are you forecasting the resulting lost recurring revenue heading into FY27?